PriceTargets.com logo

Verona Pharma PLC American Depositary Share - VRNA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $109.00
  • Forecasted Upside: 1.95%
  • Number of Analysts: 15
  • Breakdown:
  • 1 Sell Ratings
  • 12 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$106.91 As of 10/7/2025 01:00 AM ET
+0 (0.00%)
Get New Verona Pharma PLC American Depositary Share Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VRNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRNA

Analyst Price Target is $109.00
▲ +1.95% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Verona Pharma PLC American Depositary Share in the last 3 months. The average price target is $109.00, with a high forecast of $170.00 and a low forecast of $57.00. The average price target represents a 1.95% upside from the last price of $106.91.

This chart shows the closing price for VRNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 15 investment analysts is to hold stock in Verona Pharma PLC American Depositary Share. This rating has held steady since July 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 12 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 12 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 12 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 12 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/8/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$100.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/8/2025Zacks ResearchUpgradeHold
7/14/2025HC WainwrightReiterated RatingBuy ➝ Neutral$90.00 ➝ $107.00
7/10/2025Piper SandlerDowngradeStrong-Buy ➝ Hold
7/10/2025Wolfe ResearchDowngradeStrong-Buy ➝ Hold
7/10/2025Roth CapitalDowngradeStrong-Buy ➝ Hold
7/10/2025Wells Fargo & CompanyDowngradeStrong-Buy ➝ Hold$138.00 ➝ $107.00
7/10/2025BTIG ResearchDowngradeStrong-Buy ➝ Hold
7/9/2025CowenDowngradeBuy ➝ Hold
7/9/2025Truist FinancialDowngradeStrong-Buy ➝ Hold
7/9/2025TD CowenDowngradeStrong-Buy ➝ Hold
7/9/2025Canaccord Genuity GroupDowngradeStrong-Buy ➝ Hold$107.00
7/9/2025Jefferies Financial GroupReiterated RatingBuy ➝ Hold$140.00 ➝ $107.00
7/1/2025Wolfe ResearchInitiated CoverageOutperform$170.00
6/23/2025Piper SandlerSet TargetOverweight ➝ Overweight$76.00 ➝ $160.00
6/20/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$107.00 ➝ $138.00
6/18/2025Roth CapitalReiterated RatingBuy ➝ Buy$92.00 ➝ $116.00
6/11/2025Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$90.00 ➝ $100.00
6/11/2025Jefferies Financial GroupBoost TargetBuy ➝ Buy$95.00 ➝ $110.00
6/2/2025HC WainwrightBoost TargetBuy ➝ Buy$85.00 ➝ $90.00
4/30/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$93.00 ➝ $107.00
4/30/2025HC WainwrightBoost TargetBuy ➝ Buy$75.00 ➝ $85.00
4/28/2025CowenInitiated CoverageBuy
4/28/2025TD CowenInitiated CoverageBuy$100.00
4/21/2025Cantor FitzgeraldInitiated CoverageOverweight$80.00
2/28/2025Roth CapitalSet Target$83.00
2/28/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$74.00 ➝ $93.00
2/28/2025HC WainwrightBoost TargetBuy ➝ Buy$60.00 ➝ $75.00
2/12/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$44.00 ➝ $72.00
1/21/2025HC WainwrightReiterated RatingBuy ➝ Buy$42.00 ➝ $60.00
1/10/2025Roth CapitalUpgradeStrong-Buy
1/10/2025Roth MkmInitiated CoverageBuy$68.00
1/8/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$64.00 ➝ $74.00
1/8/2025Truist FinancialReiterated RatingBuy ➝ Buy$44.00 ➝ $57.00
11/5/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$50.00 ➝ $64.00
11/5/2024HC WainwrightBoost TargetBuy ➝ Buy$36.00 ➝ $42.00
11/5/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$37.00 ➝ $44.00
10/9/2024Truist FinancialBoost TargetBuy ➝ Buy$38.00 ➝ $44.00
10/3/2024Wells Fargo & CompanyInitiated CoverageOverweight$50.00
10/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
9/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
9/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
7/22/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$35.00 ➝ $37.00
6/28/2024Truist FinancialBoost TargetBuy ➝ Buy$32.00 ➝ $38.00
6/27/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
6/27/2024HC WainwrightBoost TargetBuy ➝ Buy$32.00 ➝ $36.00
5/13/2024HC WainwrightLower TargetBuy ➝ Buy$33.00 ➝ $30.00
4/16/2024Piper SandlerBoost TargetOverweight ➝ Overweight$31.00 ➝ $36.00
3/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00
3/1/2024WedbushReiterated RatingOutperform ➝ Outperform$33.00
1/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00
12/29/2023HC WainwrightReiterated RatingBuy ➝ Buy$32.00
11/2/2023WedbushReiterated RatingOutperform$33.00
10/19/2023WedbushReiterated RatingOutperform$33.00
9/13/2023WedbushReiterated RatingOutperform$30.00 ➝ $33.00
9/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$32.00
9/1/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$35.00
8/4/2023WedbushReiterated RatingOutperform$30.00
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$32.00
6/28/2023500.comReiterated RatingReiterates
6/7/2023Truist FinancialBoost Target$28.00 ➝ $32.00
3/20/2023BTIG ResearchBoost Target$26.00 ➝ $31.00
3/13/2023HC WainwrightReiterated RatingBuy$32.00
12/21/2022HC WainwrightBoost TargetBuy$30.00 ➝ $32.00
12/20/2022Truist FinancialBoost TargetBuy$20.00 ➝ $28.00
12/20/2022BTIG ResearchBoost TargetBuy$17.00 ➝ $26.00
9/19/2022WedbushReiterated RatingOutperform$27.00
8/29/2022HC WainwrightBoost TargetBuy$25.00 ➝ $30.00
8/26/2022Piper SandlerInitiated CoverageOverweight$31.00
8/10/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$24.00 ➝ $27.00
8/9/2022WedbushBoost Target$18.00 ➝ $23.00
6/21/2022HC WainwrightReiterated RatingBuy$25.00
6/17/2022WedbushLower TargetOutperform$25.00 ➝ $18.00
6/9/2022HC WainwrightReiterated RatingBuy$25.00
5/23/2022HC WainwrightReiterated RatingBuy$25.00
1/25/2022HC WainwrightReiterated RatingBuy$25.00
1/6/2022HC WainwrightReiterated RatingBuy$25.00
9/13/2021HC WainwrightInitiated CoverageBuy$25.00
6/13/2021BTIG ResearchReiterated RatingBuy$17.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 52 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 39 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 26 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 60 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 35 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 27 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 7 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Verona Pharma PLC American Depositary Share logo
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $106.91
Low: $106.91
High: $106.91

50 Day Range

MA: $106.65
Low: $105.91
High: $106.95

52 Week Range

Now: $106.91
Low: $31.09
High: $106.93

Volume

N/A

Average Volume

1,457,608 shs

Market Capitalization

$9.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Verona Pharma PLC American Depositary Share?

The following sell-side analysts have issued stock ratings on Verona Pharma PLC American Depositary Share in the last twelve months: BTIG Research, Canaccord Genuity Group Inc., Cantor Fitzgerald, Cowen Inc, HC Wainwright, Jefferies Financial Group Inc., Piper Sandler, Roth Capital, Roth Mkm, TD Cowen, Truist Financial Corporation, Weiss Ratings, Wells Fargo & Company, Wolfe Research, and Zacks Research.
View the latest analyst ratings for VRNA.

What is the current price target for Verona Pharma PLC American Depositary Share?

0 Wall Street analysts have set twelve-month price targets for Verona Pharma PLC American Depositary Share in the last year. Their average twelve-month price target is $109.00, suggesting a possible upside of 2.0%. Wolfe Research has the highest price target set, predicting VRNA will reach $170.00 in the next twelve months. Truist Financial Corporation has the lowest price target set, forecasting a price of $57.00 for Verona Pharma PLC American Depositary Share in the next year.
View the latest price targets for VRNA.

What is the current consensus analyst rating for Verona Pharma PLC American Depositary Share?

Verona Pharma PLC American Depositary Share currently has 1 sell rating, 12 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in VRNA, but not buy more shares or sell existing shares.
View the latest ratings for VRNA.

What other companies compete with Verona Pharma PLC American Depositary Share?

Other companies that are similar to Verona Pharma PLC American Depositary Share include Teva Pharmaceutical Industries, BioNTech, Genmab A/S, Revolution Medicines and Roivant Sciences. Learn More about companies similar to Verona Pharma PLC American Depositary Share.

How do I contact Verona Pharma PLC American Depositary Share's investor relations team?

Verona Pharma PLC American Depositary Share's physical mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company's listed phone number is 011-44-0-2032834200 and its investor relations email address is [email protected]. The official website for Verona Pharma PLC American Depositary Share is www.veronapharma.com. Learn More about contacing Verona Pharma PLC American Depositary Share investor relations.